Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ORGANIZATION
ORGANIZATION
- JPMA on Alert for IRA’s Drug Pricing Provisions, Boosting Cooperation with PhRMA
August 29, 2023
- As 2040 Doctor Shortage Looms, Japan Consumer Healthcare Group Pushes Rx-to-OTC Switches for Hypertension Meds
August 25, 2023
- Japan Citizens’ Group Objects to HPV Vaccination in Males
August 25, 2023
- JPMA Taskforce Issues Proposal on Information Supply, Drug Development for Rare Diseases
August 18, 2023
- Economic Burden of Preventable Cancer “Over 1 Trillion Yen”: NCC, NCGM
August 17, 2023
- INES Proposes Extension of Public Funding for COVID Drugs
August 7, 2023
- IRA Could Create New Type of Drug Loss, Affecting Japan Too: PhRMA Official
July 31, 2023
- Shipments of 22.3% of Products Restricted or Suspended in June: FPMAJ
July 24, 2023
- JPA to Issue Policy Proposal to Address Lingering Supply Crisis
July 24, 2023
- More People Seek Self-Medication Tax Break in 2022
July 24, 2023
- JPMA Says IRA Is “Alarming,” Set to Exchange Views with PhRMA
July 21, 2023
- Pseudonymised Data Should Fuel Orphan Drug Discovery, but Criteria and Overseas Usage Must Be Discussed: JPMA
July 21, 2023
- Policy Veterans’ Group Lauds Expert Panel’s Report as “Epoch Making”
July 20, 2023
- Drug Reps in Japan Decline for 9th Consecutive Year, Falling Below 50,000: FY2022 Report
July 19, 2023
- Reform Regenerative Medicine Systems to Fight Lag, Loss: FIRM to Japan Govt
July 12, 2023
- Stop Requiring Japanese PI Data for Global Products: JPMA Officials
July 10, 2023
- PhRMA Urges Japan to Offer Coverage for CGP Testing in First-Line Setting
July 4, 2023
- Generic Use Rate at 80.7% in FY2022: JGA
June 30, 2023
- Citizens’ Group Opposes Pilot Switch Program for Emergency Contraceptives
June 27, 2023
- FPMAJ Chief Shows Enthusiasm toward Drug Pricing Reform, Vows to Exchange Views with All Affiliate Groups
June 26, 2023
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…